Form 8-K - Current report:
SEC Accession No. 0001842952-25-000006
Filing Date
2025-01-14
Accepted
2025-01-14 17:03:03
Documents
15
Period of Report
2025-01-14
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cntx-20250114.htm   iXBRL 8-K 25248
2 EX-99.1 a20250114-firstpatientdose.htm EX-99.1 10942
6 image_0.jpg GRAPHIC 197973
  Complete submission text file 0001842952-25-000006.txt   447643

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cntx-20250114.xsd EX-101.SCH 1818
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cntx-20250114_lab.xml EX-101.LAB 24372
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cntx-20250114_pre.xml EX-101.PRE 14143
17 EXTRACTED XBRL INSTANCE DOCUMENT cntx-20250114_htm.xml XML 3001
Mailing Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103
Business Address 2001 MARKET STREET SUITE 3915 UNIT #15 PHILADELPHIA PA 19103 267-225-7416
Context Therapeutics Inc. (Filer) CIK: 0001842952 (see all company filings)

EIN.: 863738787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40654 | Film No.: 25530105
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)